Yohimbine bioavailability in humans
- 67 Downloads
Pharmacokinetic profiles were determined in seven healthy young male subjects following single oral and intravenous doses of 10 mg of yohimbine hydrochloride.
The drug was rapidly eliminated (t1/2β 0.58 h orally and t1/2β 0.68 h intravenously). Following intravenous administration the data fit a two-compartment pharmacokinetic model, with a very rapid distribution phase (t1/2a was approximately 6 min). Both the oral and the intravenous yohimbine clearance values were high but oral clearance values were much higher (mean 9.77 ml·min−1·kg−1 intravenous versus 55.9 ml·min−1·kg−1 oral). The oral bioavailability showed great variability, ranging from 7% to 87% (mean value was 33%).
The imcomplete oral bioavailability of yohimbine may reflect either incomplete absorption from the gastrointestinal tract or an hepatic first pass effect. Although yohimbine is rapidly absorbed when given orally, the bioavailability is quite variable and considerable individualization of dosing may be necessary when the drug is used orally for clinical indications.
Key wordsyohimbine pharmacokinetics bioavailability
Unable to display preview. Download preview PDF.
- 1.Morales A, Surridge DHC, Marshall PC, Fenemore J (1982) Nonhormonal pharmacological treatment of organic impotence. J Urol 128: 45–47Google Scholar
- 2.Reid K, Surridge DHC, Morales A, Condra M, Harris C, Owen J, Fenemore J (1987) Double-blind trial of yohimbine in treatment of psychogenic impotence. Lancet II: 421–423Google Scholar
- 3.Onrot J, Goldberg MR, Biaggioni I, Wiley RG, Hollister AS, Robertson D (1987) Oral yohimbine in human autonomic failure. Neurology 37: 215–220Google Scholar
- 4.Lacomblez L, Bensimon G, Isnard F, Diquet B, Lecrubier Y, Puech AJ (1989) Effect of yohimbine on blood pressure in patients with depression and orthostatic hypotension induced by clomipramine. Clin Pharm Ther 45: 241–251Google Scholar
- 5.Yamaguchi N (1982) Evidence supporting the existence of presynaptic α-adrenoceptors in the regulation of noradrenaline release upon hepatic sympathetic nerve stimulation in the dog liver in vivo. Naunyn-Schmiedeberg's Arch Pharmacol 321: 177–184Google Scholar
- 6.Charney DS, Heninger GR, Steinberg DE (1982) Assessment of α-adrenergic autoreceptor function in humans. Effects of oral yohimbine. Life Sci 30: 2033–2041Google Scholar
- 7.Goldstein DS, Eisenhofer G, Garty M, Sax FL, Keiser HR, Kopin IJ (1989) Pharmacologic and tracer methods to study sympathetic function in primary hypertension. Clin Exp Hypertens A 11 [Suppl 1]: 173–189Google Scholar
- 8.Charney DS, Woods SW, Goodman WK, Heninger GR (1987) Neurobiological mechanisms of panic anxiety: biochemical and behavioral correlates of yohimbine-induced panic attacks. Am J Psychiatry 144: 1030–1036Google Scholar
- 9.Owen JA, Hakatsu SL, Fenemore J, Condra M, Surridge DHC, Morales A (1987) The pharmacokinetics of yohimbine in man. Eur J Clin Pharmacol 32: 577–582Google Scholar
- 10.Hariharan M, Guthrie SK, Kindtek EK, VanNoord T, Grunhaus LJ (1990) An HPLC coulometric assay and preliminary pharmacokinetics of yohimbine in man. Clin Chem 36: 1047Google Scholar
- 11.Metzler CN, Elfring GL, McEwen AJ (1974) A user's manual for NONLIN and associated programs. Upjohn, Kalamazoo, MichiganGoogle Scholar
- 12.Gibaldi M and Perrier D (1982) Pharmacokinetics. Second edition, revised and expanded. Dekker, New York, pp 445–449Google Scholar
- 13.Statview, the graphic statistics utility for Macintosh (1985) Brain Power, Calabasas, CAGoogle Scholar